Generative AI in Life Sciences: Real Examples (2026)

95% of enterprise generative AI pilots failed to deliver measurable business impact in 2025. That gap points to one thing: real implementation versus experimentation. While most industries stayed stuck with generic productivity gains, life sciences companies pushed AI drug discovery into actual pipelines. Insilico Medicine published Phase IIa results for Rentosertib in Nature Medicine (IF=58.7) …